Table 2.
Primary Endpoints in the Teneligliptin and Control Groups
| Variable | Teneligliptin Group (n = 8) | Control Group (n = 9) | Between-Group Difference | ||
|---|---|---|---|---|---|
| Mean ± SD | P value | Mean ± SD | P value | P value | |
| EPC (/μL) | |||||
| 0 W | 0.87 ± 0.54 | 1.19 ± 0.64 | 0.29 | ||
| 28 W | 1.24 ± 0.47 | 1.12 ± 0.41 | 0.61 | ||
| 28 W-0 W | 0.37 ± 0.45 | 0.06 | −0.02 ± 0.51 | 0.91 | 0.13 |
| DPP-4 activity (μU/mL) | |||||
| 0 W | 551.0 ± 112.2 | 656.0 ± 73.8 | 0.036 | ||
| 28 W | 41.5 ± 39.4 | 676.3 ± 58.4 | <0.001 | ||
| 28 W-0 W | −509.5 ± 105.7 | <0.001 | 32.8 ± 53.4 | 0.13 | <0.001 |
| SDF-1α (pg/mL) | |||||
| 0 W | 2495.9 ± 500.6 | 2406.6 ± 428.1 | 0.70 | ||
| 28 W | 1800.3 ± 250.5 | 2522.0 ± 332.0 | <0.001 | ||
| 28 W-0 W | −695.6 ± 443.2 | 0.003 | 11.1 ± 193.7 | 0.88 | 0.001 |
Abbreviations: EPC, endothelial progenitor cell; DPP-4, dipeptidyl peptidase-4; SDF-1α, stromal cell derived factor - 1α.